Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

343 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-02

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to identify new prognostic factors in patients affected by advanced pancreatic carcinoma treated with first line chemotherapy with FOLFIRINOX regimen. Primary objective is the identification of clinical, laboratory and pathologic factors affecting overall survival of these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer

NCT02351219

Pancreatic Carcinoma Stage III

COMPLETED PHASE2

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

NCT06389552

Adjuvant Chemotherapy

RECRUITING

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

NCT02143219

Pancreatic Metastatic Cancer Toxicity

COMPLETED PHASE2

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

NCT05360732

Metastatic Pancreatic Cancer

ACTIVE_NOT_RECRUITING PHASE2

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

NCT03042780

Gastro-enteropancreatic Neuroendocrine Tumor Pancreatic Cancer Neuroendocrine Carcinomas of Pancreas +1 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer Non-resectable

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FOLFIRINOX

Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>18 years
* citologically or histologically confirmed pancreatic carcinoma
* disease stage III or IV according to the American Joint Committee on Cancer (AJCC) staging system
* access to clinical informations collected before first-line starting
* availability of objective response evaluation and survival data
* written informed consent

Exclusion Criteria

* diagnosis of other neoplasia than pancreatic carcinoma
* treatment with drugs other than FOLFIRINOX
* treatment with experimental drugs in combination with FOLFIRINOX
* unavailability of clinical and pathological data

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No